Illumina Signs Agreement to Acquire NextBio
News Oct 29, 2013
Illumina, Inc. has announced that it has signed a definitive agreement to acquire Santa Clara-based NextBio, a leader in clinical and genomic informatics.
NextBio's powerful big-data platforms aggregate and analyze large quantities of phenotypic and genomic data for research and clinical applications.
With the addition of NextBio's platform upon completion of the acquisition, Illumina will be able to offer customers enterprise level bioinformatics solutions that accelerate the discovery of new associations between the human genome and disease, and ultimately, enable the application of those discoveries within healthcare.
"This agreement with NextBio demonstrates Illumina's unwavering commitment to drive the adoption of sequencing in new markets and vastly improve the genomic information workflow," said Jay Flatley, President and CEO of Illumina.
Flatley continued, "NextBio enables the classification and aggregation of phenotypic and clinical data within a single environment and allows analysis of that data at unprecedented speed and scale. The combination of Illumina's BaseSpace cloud computing environment for next-generation sequencing with NextBio's platform for integrating patient data will allow us to deliver solutions that seamlessly integrate the entire workflow from sample to result."
NextBio's platform allows customers to quickly compare their experimental results against thousands of published and private data sets by means of a unique correlation engine, which pre-computes billions of significant connections between disparate data elements and helps discover new associations.
NextBio Clinical, which in 2012 passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems.
Backed by highly scalable Software as a Service (SaaS) enterprise technology, it is capable of analyzing petabytes of data.
NextBio's database platforms are currently used by researchers and clinicians in more than 50 commercial and academic institutions. NextBio will be integrated into Illumina's newly formed Enterprise Informatics business under the leadership of Nick Naclerio, SVP of Corporate and Venture Development and General Manager of Enterprise Informatics.
NextBio co-founder Ilya Kupershmidt and Chief Technology Officer Satnam Alag will continue to provide scientific and technical leadership as part of the new business unit.
Illumina is confirming its 2013 financial guidance provided on October 21, 2013. The transaction is expected to close by the end of October.
Toothpaste Ingredient Could Help Fight Drug-Resistant MalariaNews
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs.READ MORE
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Watch: Genome Packaging Revealed in Unprecedented DetailNews
A new study has answered century-old questions about how chromosome folding occurs.READ MORE